Spectrum Pharmaceuticals Inc. (SPPI)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

11500 S. EASTERN AVE., SUITE 240 HENDERSON, NV 89052

Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer, or NMIBC, and is under strategic collaborations with Nippon Kayaku Co. Ltd.(Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat, is being studied in multiple indications including a Phase II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.

Data based on most recent fiscal year report
Market Cap344.559 Million Shares Outstanding112.97 Million Avg Volume1.572 Million
1-Yr BETA vs S&P TR1.612 Current Ratio2.9 Quick Ratio2.86
View SEC Filings from SPPI instead.

View recent insider trading info

Funds Holding SPPI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SPPI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

26.2 Thousand total shares from 6 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

TURGEON JOSEPH W. CEO & PRESIDENT

  • Officer
  • Director
425,280 2020-01-16 6

GUSTAFSON KURT A EVP & CHIEF FINANCIAL OFFICER

  • Officer
240,001 2020-01-16 5

RIGA THOMAS J EVP, COO & CCO

  • Officer
249,776 2020-01-16 5

COHEN RAYMOND W CHIEF EXECUTIVE OFFICER

608,391 2020-01-13 2

ASHTON WILLIAM

  • Director
27,782 2019-12-05 1

ALLEN LEE F MD PHD CHIEF MEDICAL OFFICER

  • Officer
0 2019-11-12 0

LEBEL FRANCOIS CHIEF MEDICAL OFFICER

  • Officer
115,155 2019-11-06 3

TIDMARSH GEORGE F

  • Director
151,291 2019-09-19 0

MCGAHAN KEITH M CHIEF LEGAL OFFICER

  • Officer
137,723 2019-08-12 7

SCOTT BRETT L

  • Director
30,575 2019-07-23 0

VACIRCA JEFF L

  • Director
23,231 2019-06-26 4

SHROTRIYA RAJESH C MD

  • Director
0 2019-06-20 0

VYAS DOLATRAI

  • Director
51,069 2019-06-20 1

WELLES BERNICE R

  • Director
20,000 2019-06-20 1

CZEREPAK ELIZABETH

  • Director
10,000 2019-06-20 2

GUETH ANTON

  • Director
326,749 2019-06-13 0

MAIDA ANTHONY E III

  • Director
0 2019-05-31 4

KRASSNER STUART MITCHELL

  • Director
75,488 2019-05-24 1

GAGNON GILLES

  • Director
72,500 2018-10-09 0

LENAZ LUIGI MD

  • Director
109,077 2018-05-22 0

KELLER JOSEPH KENNETH EVP & CHIEF OPERATING OFFICER

  • Officer
168,000 2013-12-03 0

ARORA KRISHAN K

  • Director
15,000 2012-12-19 0

SHIELDS JAMES CHIEF COMMERCIAL OFFICER

  • Officer
0 2012-09-07 0

MEHTA DILIP J MD PHD

  • Director
0 2011-06-12 0

KUMARIA SHYAM K SR. VICE PRESIDENT FINANCE

  • Officer
No longer subject to file 2011-01-03 0

VIDA JULIUS A

  • Director
0 2010-04-20 0

FULMER RICHARD

  • Director
0 2010-04-20 0

CYBULSKI MITCHELL P.

  • Director
0 2010-04-20 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GUSTAFSON KURT A - Officer EVP & CHIEF FINANCIAL OFFICER

2020-01-17 S 1,621 $3.33 d 231,955 240,001.00 direct yes

TURGEON JOSEPH W. - Director - Officer CEO & PRESIDENT

2020-01-17 S 1,944 $3.33 d 425,280 425,280.00 direct yes

RIGA THOMAS J - Officer EVP, COO & CCO

2020-01-17 S 5,000 $3.26 d 241,678 249,776.00 direct yes

TURGEON JOSEPH W. - Director - Officer CEO & PRESIDENT

2020-01-16 S 3,753 $3.37 d 427,224 425,280.00 direct yes

RIGA THOMAS J - Officer EVP, COO & CCO

2020-01-16 S 11,381 $3.37 d 246,678 249,776.00 direct yes

GUSTAFSON KURT A - Officer EVP & CHIEF FINANCIAL OFFICER

2020-01-16 S 2,522 $3.37 d 233,576 240,001.00 direct yes
Click here to report any possible errors with this stock listing.

Elevate your investments